News for Ionis Pharmaceuticals, Inc. (IONS.MX)

[url=

**media[553406]**

Strengths: Innovative AOC platform and robust pipeline with potential for significant market impact.Weaknesses: Lack of commercialization experience and high R

Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 million Achieved record qua

**media[550847]**

Ionis Pharmaceuticals Inc (IONS) has announced its management team will participate in a series of fireside chats at several prestigious investor conferences in

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Raymond

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Ionis Pharmaceuticals, Inc.

The following slide deck was published by Ionis Pharmaceuticals, Inc.

On December 31, 2024, BB Biotech AG made a significant move in the biotechnology sector by acquiring an additional 5,114,399 shares of Macrogenics Inc. This tra

On December 31, 2024, BB Biotech AG executed a notable stock transaction by acquiring 750,000 shares of Esperion Therapeutics Inc. This acquisition was made at

On December 31, 2024, BB Biotech AG executed a significant transaction involving Agios Pharmaceuticals Inc. The firm reduced its holdings by 515,642 shares at a

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands against...

On January 31, 2025, T. Rowe Price Investment Management, Inc. (Trades, Portfolio) executed a significant transaction by acquiring an additional 1,683,747 share

On February 4, 2025, Patrick O'neil, Executive Vice President, Chief Legal Officer & General Counsel at Ionis Pharmaceuticals Inc (IONS), sold 6,165 shares of t

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Ionis Pharmaceuticals, Inc.

While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Learn about Ionis Pharmaceuticals' innovative RNA-targeted therapy and their potential for significant revenue growth. Read my IONS thesis.